Safety of low-intensity extracorporeal shock wave therapy in prostate disorders: in vitro and in vivo evidence.

Autor:	Wang YR; Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou 730000, China., Feng B; Department of Urology, Gansu Provincial Hospital, Lanzhou 730000, China., Qi WB; Department of Radiotherapy, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China., Gong YW; Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou 730000, China., Kong XB; Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou 730000, China., Cheng H; Department of Urology, Gansu Provincial Second People's Hospital, Lanzhou 730000, China., Dong ZL; Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou 730000, China., Tian JQ; Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou 730000, China., Wang ZP; Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou 730000, China.
Jazyk:	angličtina
Zdroj:	Asian journal of andrology [Asian J Androl] 2024 Sep 01; Vol. 26 (5), pp. 535-543. Date of Electronic Publication: 2024 Aug 06.
DOI:	10.4103/aja202448
Abstrakt:	Abstract: Recent evidence suggests that low-intensity extracorporeal shock wave therapy (Li-ESWT) is a promising treatment for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS); however, its safety in pelvic organs, particularly prostate tissues and cells, remains unclear. The current study evaluates the risks of prostate cell damage or oncogenesis following the administration of Li-ESWT for prostatitis. To this end, a robust in vitro model (Cell Counting Kit-8 [CCK-8] assay, clone formation assay, cell scratch assay, lactate dehydrogenase [LDH] release assay, flow cytometry, and immunoblotting assay) was designed to examine the effects of Li-ESWT on cell proliferation, clonogenicity, migration, membrane integrity, and DNA damage. Exome sequencing of Li-ESWT-treated cells was performed to determine the risk of carcinogenesis. Furthermore, an in vivo rat model ( n = 20) was employed to assess the effects of Li-ESWT on cancer biomarkers (carcinoembryonic antigen [CEA], Ki67, proliferating cell nuclear antigen [PCNA], and gamma-H2A histone family member X, phosphorylation of the H2AX Ser-139 [ γ -H2AX]) in prostate tissue. Based on our findings, Li-ESWT promotes cellular growth and motility without inducing significant cell membrane or DNA damage or alterations. Genetic analyses did not demonstrate an increase in mutations, and no damage to prostate tissue or upregulation of cancer biomarkers was detected in vivo. This comprehensive in vitro and in vivo assessment confirms the safety of Li-ESWT in managing prostate disorders. (Copyright © 2024 Copyright: ©The Author(s)(2024).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu